These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30940667)

  • 1. Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS).
    Benger M; Vink J; Snell LB; Breen K
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30940667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.
    Dufrost V; Risse J; Zuily S; Wahl D
    Curr Rheumatol Rep; 2016 Dec; 18(12):74. PubMed ID: 27812956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rethinking the use of direct oral anticoagulants for secondary thromboprophylaxis in patients with thrombotic antiphospholipid syndrome.
    Franco-Moreno A; Izquierdo-Martínez A; Ancos-Aracil C
    Drug Discov Ther; 2024 Sep; 18(4):213-219. PubMed ID: 39198152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome.
    Liu A; Rupani KV; Naymagon L
    Eur J Haematol; 2022 Jul; 109(1):69-74. PubMed ID: 35305281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
    Pengo V; Denas G; Zoppellaro G; Jose SP; Hoxha A; Ruffatti A; Andreoli L; Tincani A; Cenci C; Prisco D; Fierro T; Gresele P; Cafolla A; De Micheli V; Ghirarduzzi A; Tosetto A; Falanga A; Martinelli I; Testa S; Barcellona D; Gerosa M; Banzato A
    Blood; 2018 Sep; 132(13):1365-1371. PubMed ID: 30002145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
    Malec K; Góralczyk T; Undas A
    Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
    Resseguier AS; Pereira B; Rieu V; Le Guenno G; Grobost V; Ruivard M
    Lupus; 2017 Oct; 26(12):1297-1303. PubMed ID: 28355988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
    Cohen H; Doré CJ; Clawson S; Hunt BJ; Isenberg D; Khamashta M; Muirhead N;
    Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
    Cohen H; Hunt BJ; Efthymiou M; Arachchillage DR; Mackie IJ; Clawson S; Sylvestre Y; Machin SJ; Bertolaccini ML; Ruiz-Castellano M; Muirhead N; Doré CJ; Khamashta M; Isenberg DA;
    Lancet Haematol; 2016 Sep; 3(9):e426-36. PubMed ID: 27570089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct oral anticoagulants in antiphospholipid syndrome: a real life case series.
    Betancur JF; Bonilla-Abadía F; Hormaza AA; Jaramillo FJ; Cañas CA; Tobón GJ
    Lupus; 2016 May; 25(6):658-62. PubMed ID: 26743321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
    Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
    Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review.
    Girón-Ortega JA; Girón-González JA
    Med Clin (Barc); 2023 Jul; 161(2):65-77. PubMed ID: 37105842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Bauersachs R; Schellong S; Stücker M; Oldenburg J; Kalka C; Scholz U; Lindhoff-Last E
    Hamostaseologie; 2019 Aug; 39(3):298-300. PubMed ID: 31404932
    [No Abstract]   [Full Text] [Related]  

  • 14. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
    Ann Intern Med; 2019 Nov; 171(10):. PubMed ID: 31610579
    [No Abstract]   [Full Text] [Related]  

  • 15. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
    Ordi-Ros J; Sáez-Comet L; Pérez-Conesa M; Vidal X; Riera-Mestre A; Castro-Salomó A; Cuquet-Pedragosa J; Ortiz-Santamaria V; Mauri-Plana M; Solé C; Cortés-Hernández J
    Ann Intern Med; 2019 Nov; 171(10):685-694. PubMed ID: 31610549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study.
    Malec K; Broniatowska E; Undas A
    Lupus; 2020 Jan; 29(1):37-44. PubMed ID: 31757182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
    Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
    J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Would you use novel oral anticoagulants (NOACs) for thromboprophylaxis in patients with an underlying hypercoagulable state? A literature review through a case report.
    Kakadia B; Suero-Abreu GA; Daci R; Then RK
    BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33127703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 20. Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study.
    Sato T; Nakamura H; Fujieda Y; Ohnishi N; Abe N; Kono M; Kato M; Oku K; Bohgaki T; Amengual O; Yasuda S; Atsumi T
    Lupus; 2019 Nov; 28(13):1577-1582. PubMed ID: 31635559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.